Jean McGee is a Dermatology physician affiliated with Brigham and Women's Hospital. OpenAlex indexes 82 publications with 757 citations (h-index 15).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
725 Albany Street
Shapiro 8b
Boston, MA 021182515
Telephone
617-638-7420Registry record last updated 15 Jul 2016.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novartis Pharmaceuticals CorporationProgram year20241 payment
- ABBVIE INC.Program year20241 payment
- Incyte CorporationProgram year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
54.2%Lincosamide Antibacterial30.6%Clindamycin Phosphate100%Part D<11 patientsAzole Antifungal23.6%Ketoconazole100%Part D<11 patientsDermatology
45.8%Corticosteroid25%Triamcinolone Acetonide100%Part D≥15 patientsInterleukin-4 Receptor alpha Antagonist20.8%Dupixent Pen100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2023–2026 per NIH RePORTER. The latest:
- Multi-omic Studies of Local and Systemic Immune Dysregulation in Rosacea
Brigham and Women'S Hospital
FY2026$169,884K23AR080203 - Multi-omic Studies of Local and Systemic Immune Dysregulation in Rosacea
Brigham and Women'S Hospital
FY2025$169,884K23AR080203 - Multi-omic Studies of Local and Systemic Immune Dysregulation in Rosacea
Brigham and Women'S Hospital
FY2024$169,884K23AR080203
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Use of biologic therapies in the management of pyoderma gangrenosum: a systematic review
Archives of Dermatological Research
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Paul Ridker, MD
Brigham and Women's Hospital
Scott Solomon, MD
Brigham and Women's Hospital
Dennis Selkoe, MD
Brigham and Women's Hospital
Marc Pfeffer, MD
Brigham and Women's Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”